Hepion Pharmaceuticals, Inc. 8-K

What Happened

• Hepion Pharmaceuticals, Inc. (HEPA) announced on its 8-K that on February 25, 2026 it entered into an intellectual property license agreement with Cirna Diagnostics, LLC to in‑license liver disease diagnostic assets.
• The agreement covers a novel biomarker assay that detects mutant circulating tumor RNA to help facilitate early diagnosis of hepatocellular carcinoma (HCC) in high‑risk patients. A press release announcing the deal was issued on March 3, 2026 and is included as an exhibit to the filing.

Key Details

• Upfront payment: $50,000.
• Additional obligations: payment of certain patent expenses.
• Milestones: up to $2,350,000 in development/other milestones and up to $4,500,000 in sales‑based milestone payments (total potential milestones $6,850,000).
• Royalties: low single‑digit royalty on net sales if commercialized.

Why It Matters

• The deal expands Hepion’s intellectual property and product scope into diagnostics for HCC, potentially creating a new pathway to revenue if the assay is developed and commercialized.
• Financial exposure today is limited (small upfront), with larger payments contingent on achieving milestones and sales; royalties are modest (low single digits).
• For investors, the agreement is a strategic licensing arrangement rather than an acquisition—important to monitor future clinical/validation progress, regulatory steps, and any updates on commercialization or revenue milestones announced by the company.